1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAdvancing Evidence in HIV Treatment: Using other VH Product besides Cabotegravir and Dolutegravir/Lamivudine (General) is sponsored by ViiV Healthcare. ViiV Healthcare welcomes investigator-sponsored research that advances the understanding of HIV treatment using ViiV Healthcare products other than Cabotegravir and Dolutegravir/Lamivudine.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
## Advancing Evidence in HIV Treatment: Using other VH Product besides Cabotegravir and Dolutegravir/Lamivudine (General) ViiV Healthcare welcomes investigator-sponsored research that advances understanding of HIV treatment using other VH products besides Cabotegravir and Dolutegravir/Lamivudine.
Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.
## ViiV ISR Area Of Interest Overview ViiV Products in Scope:Other Specify the Treatment Type: Area of Interest/DataGap Description Example Research Question(s):All scientifically sound and relevant research questions that advance evidence in HIV treatment using other VH products besides Cabotegravir and Dolutegravir are welcome. Desirable Study Parameters Populations of Interest:All Patient Types Geographical Regions:Global
According to the current listing, eligibility includes: Investigators capable of conducting scientifically sound research using ViiV Healthcare products to advance evidence in HIV treatment. Confirm the full requirements in the official notice before applying.
Advancing Evidence in HIV Treatment: Using other VH Product besides Cabotegravir and Dolutegravir/Lamivudine (General) is funded by ViiV Healthcare. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Research Grants (for Comprehensive Fiber Database) is sponsored by Institute for the Advancement of Food and Nutrition Sciences (IAFNS). Supports research based primarily on the Comprehensive Fiber Database developed and maintained by Tufts University. Projects may include evidence reviews of fiber and health outcomes, or knowledge/gap analysis of specific fiber areas related to human health.
Inclusive Teaching Transformation Grants is sponsored by Elon University, Center for the Advancement of Teaching & Learning (CATL). These grants support teams of faculty developing evidence-based and inclusive teaching practices that foster success for students of all academic and social backgrounds, including developing materials for a course or program to pilot best practices in inclusive pedagogy.
USDA's FY2026 GusNIP Produce Prescription Program will make roughly 12 awards of up to $500,000 over three years — with no matching requirement — to nonprofits and government agencies that partner with healthcare providers to prescribe fresh fruits and vegetables. Here is who is eligible, why the mandatory clinical partner is the whole game, how the evidence base got strong enough to matter, and how to build a July 16 application.
Read articleDespite NIH budget pressure, hundreds of millions in AI healthcare research grants remain active in 2026. Full breakdown of Bridge2AI, AHRQ patient safety, NSF/NIH Smart Health, BARDA, Gates Foundation, and Google.org — with eligibility, amounts, and current deadlines.
Read articleThe Rural Health Care Program's Third Further Notice hit the Federal Register on August 31, 2026. It proposes killing cost studies, publishing an eligible services list, setting application processing deadlines, and eliminating the Healthcare Connect Fund annual report. What it conspicuously does not propose is any change to the $744.2 million cap that the whole proceeding says is under strain.
Read article